CN1754876A - 一种高纯度来曲唑的制备方法 - Google Patents
一种高纯度来曲唑的制备方法 Download PDFInfo
- Publication number
- CN1754876A CN1754876A CN 200410080092 CN200410080092A CN1754876A CN 1754876 A CN1754876 A CN 1754876A CN 200410080092 CN200410080092 CN 200410080092 CN 200410080092 A CN200410080092 A CN 200410080092A CN 1754876 A CN1754876 A CN 1754876A
- Authority
- CN
- China
- Prior art keywords
- formula
- letrozole
- compound
- salt
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960003881 letrozole Drugs 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- -1 vitriol Chemical compound 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000003021 water soluble solvent Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410080092 CN100560573C (zh) | 2004-09-28 | 2004-09-28 | 一种高纯度来曲唑的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410080092 CN100560573C (zh) | 2004-09-28 | 2004-09-28 | 一种高纯度来曲唑的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1754876A true CN1754876A (zh) | 2006-04-05 |
CN100560573C CN100560573C (zh) | 2009-11-18 |
Family
ID=36688465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410080092 Expired - Lifetime CN100560573C (zh) | 2004-09-28 | 2004-09-28 | 一种高纯度来曲唑的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100560573C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7465749B2 (en) | 2005-11-14 | 2008-12-16 | Chemagis, Ltd. | Letrozole purification process |
US7538230B2 (en) | 2005-11-14 | 2009-05-26 | Chemagis Ltd. | Letrozole production process |
WO2011000396A1 (en) * | 2009-07-02 | 2011-01-06 | Synthon B.V. | Purification of letrozole intermediate |
WO2012025762A3 (en) * | 2010-08-27 | 2012-05-03 | Generics [Uk] Limited | Pure intermediate for preparing letrozole |
CN103435563A (zh) * | 2013-08-22 | 2013-12-11 | 江苏苏南药业实业有限公司 | 一种来曲唑的制备方法 |
CN103601691A (zh) * | 2013-10-17 | 2014-02-26 | 连云港杰瑞药业有限公司 | 一种高纯度4-[1-(1,2,4-三氮唑)甲基]-苯腈的制备方法 |
CN103664810A (zh) * | 2013-12-11 | 2014-03-26 | 深圳劲创生物技术有限公司 | 一种合成来曲唑的工艺 |
CN109721558A (zh) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途 |
CN109721557A (zh) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途 |
CN113620893A (zh) * | 2020-05-09 | 2021-11-09 | 杭州中美华东制药有限公司 | 一种来曲唑的制备方法 |
-
2004
- 2004-09-28 CN CN 200410080092 patent/CN100560573C/zh not_active Expired - Lifetime
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7538230B2 (en) | 2005-11-14 | 2009-05-26 | Chemagis Ltd. | Letrozole production process |
GB2432583B (en) * | 2005-11-14 | 2010-06-23 | Chemagis Ltd | Letrozole production process |
US7465749B2 (en) | 2005-11-14 | 2008-12-16 | Chemagis, Ltd. | Letrozole purification process |
WO2011000396A1 (en) * | 2009-07-02 | 2011-01-06 | Synthon B.V. | Purification of letrozole intermediate |
AU2011294906B2 (en) * | 2010-08-27 | 2016-05-19 | Generics [Uk] Limited | Pure intermediate for preparing letrozole |
WO2012025762A3 (en) * | 2010-08-27 | 2012-05-03 | Generics [Uk] Limited | Pure intermediate for preparing letrozole |
CN103298795A (zh) * | 2010-08-27 | 2013-09-11 | 基因里克斯(英国)有限公司 | 用于制备来曲唑的纯中间体 |
JP2013536217A (ja) * | 2010-08-27 | 2013-09-19 | ジェネリクス・[ユーケー]・リミテッド | 純粋な中間体 |
AU2011294906A8 (en) * | 2010-08-27 | 2016-05-26 | Generics [Uk] Limited | Pure intermediate for preparing letrozole |
CN103435563A (zh) * | 2013-08-22 | 2013-12-11 | 江苏苏南药业实业有限公司 | 一种来曲唑的制备方法 |
CN103601691A (zh) * | 2013-10-17 | 2014-02-26 | 连云港杰瑞药业有限公司 | 一种高纯度4-[1-(1,2,4-三氮唑)甲基]-苯腈的制备方法 |
CN103664810A (zh) * | 2013-12-11 | 2014-03-26 | 深圳劲创生物技术有限公司 | 一种合成来曲唑的工艺 |
CN103664810B (zh) * | 2013-12-11 | 2016-09-14 | 深圳劲创生物技术有限公司 | 一种合成来曲唑的工艺 |
CN109721558A (zh) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途 |
CN109721557A (zh) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途 |
CN113620893A (zh) * | 2020-05-09 | 2021-11-09 | 杭州中美华东制药有限公司 | 一种来曲唑的制备方法 |
CN113620893B (zh) * | 2020-05-09 | 2023-10-03 | 杭州中美华东制药有限公司 | 一种来曲唑的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100560573C (zh) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100560573C (zh) | 一种高纯度来曲唑的制备方法 | |
CN112020498A (zh) | 一种布瓦西坦中间体、其制备方法及布瓦西坦的制备方法 | |
EP1770084A1 (en) | Method for producing (z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethyl cyclopropane hydrochloride | |
CN102584692B (zh) | 盐酸吡哆醇的制备方法 | |
CN112062669A (zh) | 芳烃类化合物的制备方法 | |
CN101514163B (zh) | 光学纯西布曲明及其衍生盐的制备工艺 | |
CN114163380A (zh) | 阿伐可泮中间体及其制备方法和用途 | |
CN111320664B (zh) | 一种24-胆烯烯酸乙酯的制备方法 | |
CN108218649B (zh) | 普瑞巴林及其中间体的合成方法 | |
CN108033902A (zh) | 一种高纯度贝利司他顺式异构体的制备方法 | |
CN109160934A (zh) | 一种维库溴铵位置异构体杂质制备方法 | |
CN112778180B (zh) | 维生素d2的制备方法 | |
CN107513010A (zh) | 一种高纯度联苯乙酮的制备方法 | |
CN111662233B (zh) | 一种一步法合成4-氯-1h-咪唑-2-羧酸乙酯的方法 | |
CN115716859B (zh) | 一种脑甾醇中间体胆甾-5,24-双烯-3-醋酸酯的制备方法 | |
CN115991655B (zh) | 一种重酒石酸间羟胺及其关键中间体对映异构体的合成方法和产品 | |
CN112079894B (zh) | 一种左炔诺孕酮药典杂质v的制备方法 | |
CN111320663B (zh) | 一种24-胆烯烯酸乙酯中间体的制备方法 | |
CN109400493A (zh) | 沙库比曲及其中间体的制备方法 | |
CN110759831B (zh) | 制备常山酮中间体2-氨基-4-溴-5-氯苯甲酸方法 | |
CN111349012B (zh) | 一种卤代芳烃类化合物的制备方法及其中间体 | |
KR20040044636A (ko) | 에틸 4-(1-이미다졸일메틸)신나메이트의 정제방법 | |
CN117946199A (zh) | 一种屈螺酮关键中间体的制备方法 | |
KR100958678B1 (ko) | 시스-디메크로틴산 및 이의 염의 제조방법 | |
WO2005019229A1 (en) | Process for purification of boronic acid and its derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: AVENTIS PHARMA (HAINAN) CO., LTD. Free format text: FORMER OWNER: BEIJING D-VENTURE PHARM. T. CORP. Effective date: 20110810 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100089 HAIDIAN, BEIJING TO: 570314 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110810 Address after: 570314 No. 279 Nanhai Road, Hainan, Haikou Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100089 Beijing city Haidian District Sijiqing Wanquan Zhuang 3 Building Patentee before: Beijing D-Venture Pharmaceutical Technology Corp. |
|
DD01 | Delivery of document by public notice |
Addressee: Zhai Zhirui Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
CX01 | Expiry of patent term |
Granted publication date: 20091118 |